Rhabdomyosarcoma laboratory findings

Revision as of 15:25, 4 February 2019 by Shadan Mehraban (talk | contribs)
Jump to navigation Jump to search

Rhabdomyosarcoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Rhabdomyosarcoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Rhabdomyosarcoma laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Rhabdomyosarcoma laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Rhabdomyosarcoma laboratory findings

CDC on Rhabdomyosarcoma laboratory findings

Rhabdomyosarcoma laboratory findings in the news

Blogs on Rhabdomyosarcoma laboratory findings

Directions to Hospitals Treating Rhabdomyosarcoma

Risk calculators and risk factors for Rhabdomyosarcoma laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: {{S.M}

Overview

Laboratory Findings

  • The essential laboratory tests for patients for rhabdomyosarcoma are:[1][2]
    • CBC:
      • It may result into pancytopenia and anemia due to bone involvement.
    • Liver function test ( LFT):
      • LFT should be evaluated before chemotharapy and for assessment of liver metastasis.
    • Renal function test:
      • BUN and Creatinine levels should be evaluated before chemotherapy.
    • Blood electrolytes such as sodium, potassium, chlorine, calcium, phosphorous, and magnesium:
      • Hypercalcemia may occur.
      • These tesets should be evaluated before chemotherapy.
    • Coagulation studies:
      • Disseminated intravascular coagulation may occur.


References

  1. Fiegl M, Weltermann A, Stindl R, Fonatsch C, Lechner K, Gisslinger H (1999). "Massive disseminated intravascular coagulation and hyperfibrinolysis in alveolar rhabdomyosarcoma: case report and review of the literature". Ann Hematol. 78 (7): 335–8. PMID 10466447.
  2. Kawasaki H, Takayama J, Nagasaki K, Yamaguchi K, Ohira M (1998). "Hypercalcemia in children with rhabdomyosarcoma". J Pediatr Hematol Oncol. 20 (4): 327–9. PMID 9703006.

Template:WH Template:WS